OPKO Health’s (OPK) Outperform Rating Reiterated at Barrington Research

Barrington Research reissued their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a research note released on Friday morning,Benzinga reports. Barrington Research currently has a $2.25 price objective on the biotechnology company’s stock.

OPK has been the topic of a number of other research reports. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th.

OPKO Health Stock Up 6.7 %

NASDAQ:OPK opened at $1.74 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market capitalization of $1.19 billion, a P/E ratio of -9.16 and a beta of 1.63. The company’s 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.55. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.84.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. On average, equities analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost bought 67,434 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the acquisition, the chief executive officer now directly owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. This trade represents a 0.03 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders acquired 1,389,971 shares of company stock valued at $2,124,442. 47.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after buying an additional 8,064 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of OPKO Health by 2.3% during the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares during the last quarter. FMR LLC lifted its position in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the last quarter. Comerica Bank raised its stake in shares of OPKO Health by 18.2% in the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 16,369 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of OPKO Health by 4.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 18,571 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.